Equities Analysts Offer Predictions for ALDX Q3 Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for Aldeyra Therapeutics in a note issued to investors on Monday, May 19th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings of ($0.23) per share for the quarter, down from their previous estimate of ($0.17). The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics' Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.85) EPS, FY2026 earnings at $1.90 EPS, FY2027 earnings at ($0.35) EPS and FY2028 earnings at $0.85 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.08.

A number of other research firms also recently commented on ALDX. Wall Street Zen upgraded Aldeyra Therapeutics to a "sell" rating in a research report on Wednesday, May 21st. BTIG Research decreased their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, May 19th.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ ALDX traded up $0.07 during mid-day trading on Thursday, reaching $2.29. The company's stock had a trading volume of 305,835 shares, compared to its average volume of 788,583. The firm has a market capitalization of $136.86 million, a PE ratio of -2.37 and a beta of 0.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The stock has a fifty day moving average of $3.03 and a two-hundred day moving average of $4.60. Aldeyra Therapeutics has a 52 week low of $1.14 and a 52 week high of $7.20.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALDX. SG Americas Securities LLC raised its position in Aldeyra Therapeutics by 14.4% during the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock valued at $112,000 after purchasing an additional 2,822 shares during the period. U.S. Capital Wealth Advisors LLC bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at approximately $69,000. AlphaCentric Advisors LLC bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at approximately $234,000. Boston Financial Mangement LLC bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at approximately $141,000. Finally, Raymond James Financial Inc. bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at approximately $3,628,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the sale, the insider now directly owns 5,875,851 shares in the company, valued at $8,343,708.42. This represents a 36.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 9.60% of the stock is owned by company insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.